Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1/2 4Phase 1 4Phase 4 1Phase 3 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Carcinoma, Non-Small-Cell Lung 24Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Lung Neoplasms 11Neoplasm Metastasis 10Carcinoma, Hepatocellular 9Breast Neoplasms 9Ovarian Neoplasms 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 7Advanced Solid Tumors 7Melanoma 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Recurrence 3Multiple Myeloma 3Head and Neck Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Advanced Solid Tumours 3Vulvar Neoplasms 2Vaginal Neoplasms 2Solid Tumor 2

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × durvalumab × Clear all
NCT06551142 2026-05-22

PanTumor-101

GlaxoSmithKline

Phase 1 Recruiting
845 enrolled
Tumor-Agnostic

Neoplasms

NCT03946800 2024-10-02

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Completed
61 enrolled
Tumor-Agnostic

Neoplasms

NCT02705482 2019-08-26

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Completed
58 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT02556463 2018-12-19

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

MedImmune LLC

Phase 1 Terminated
53 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡